2-morpholin-4-yl-pyrimidines as PI3K inhibitors

Details for Australian Patent Application No. 2008237717 (hide)

International Classifications

Event Publications

5 November 2009 PCT application entered the National Phase

PCT publication WO2008/125835 Priority application(s): WO2008/125835

17 December 2009 Amendment Made

The nature of the amendment is: Amend the co-applicant name from The Institute of Cancer Research to The Institute of Cancer Research: Royal Cancer Hospital

15 December 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.